IN2015DN03733A - - Google Patents
Info
- Publication number
- IN2015DN03733A IN2015DN03733A IN3733DEN2015A IN2015DN03733A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A IN 3733DEN2015 A IN3733DEN2015 A IN 3733DEN2015A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A
- Authority
- IN
- India
- Prior art keywords
- scaffold
- ester
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725949P | 2012-11-13 | 2012-11-13 | |
| PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03733A true IN2015DN03733A (https=) | 2015-09-18 |
Family
ID=49725346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3733DEN2015 IN2015DN03733A (https=) | 2012-11-13 | 2013-11-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9765031B2 (https=) |
| EP (1) | EP2919779B1 (https=) |
| JP (1) | JP6272626B2 (https=) |
| CN (1) | CN104884057B (https=) |
| CA (1) | CA2889697C (https=) |
| IN (1) | IN2015DN03733A (https=) |
| WO (1) | WO2014078309A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104884057B (zh) | 2012-11-13 | 2019-08-20 | 美国政府(由卫生和人类服务部的部长所代表) | 大麻素受体介导的化合物 |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| JP6762930B2 (ja) * | 2014-05-09 | 2020-09-30 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用 |
| WO2016196646A1 (en) * | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
| WO2017151802A1 (en) * | 2016-03-04 | 2017-09-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
| US20230174493A1 (en) * | 2020-03-24 | 2023-06-08 | Inversago Pharma Inc. | Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors |
| EP4132912A4 (en) * | 2020-04-07 | 2024-05-01 | Inversago Pharma Inc. | PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES |
| EP4482490A4 (en) * | 2022-02-24 | 2025-08-20 | Novo Nordisk As | METHODS OF TREATING SUBJECTS WITH HYPERTRIGLYCERIDEMIA, ABDOMINAL OBESITY AND/OR ALTERED GLUCOSE |
| WO2023177568A1 (en) * | 2022-03-14 | 2023-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor modulating compounds |
| WO2025257151A1 (en) | 2024-06-10 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for treating ciliopathies |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1256638A (en) | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| DZ3335A1 (fr) | 2000-03-23 | 2001-09-27 | Solvay Pharm Bv | Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1 |
| PL363751A1 (en) * | 2001-03-22 | 2004-11-29 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| IL157704A0 (en) | 2001-09-21 | 2004-03-28 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having potent cbi-antagonistic activity |
| KR100903760B1 (ko) * | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| HRP20080549T3 (en) | 2004-01-30 | 2008-11-30 | Solvay Pharmaceuticals B.V. | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| EP1574211A1 (en) * | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
| CN101484161A (zh) | 2006-05-05 | 2009-07-15 | 詹里恩探索公司 | 大麻素受体拮抗剂/反向激动剂 |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| EP2231615A1 (en) | 2007-12-10 | 2010-09-29 | 7TM Pharma A/S | Cannabinoid receptor modulators |
| WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| WO2011044370A1 (en) | 2009-10-07 | 2011-04-14 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| US8580768B2 (en) * | 2010-11-18 | 2013-11-12 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| CN104884057B (zh) | 2012-11-13 | 2019-08-20 | 美国政府(由卫生和人类服务部的部长所代表) | 大麻素受体介导的化合物 |
| JP6762930B2 (ja) | 2014-05-09 | 2020-09-30 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | カンナビノイド受容体メディエータとしてのピラゾール誘導体およびそれらの使用 |
| WO2016196646A1 (en) | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en not_active Ceased
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
-
2017
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2919779A1 (en) | 2015-09-23 |
| WO2014078309A8 (en) | 2015-05-21 |
| CN104884057B (zh) | 2019-08-20 |
| US20180022706A1 (en) | 2018-01-25 |
| JP6272626B2 (ja) | 2018-01-31 |
| EP2919779B1 (en) | 2021-01-06 |
| US20160039766A1 (en) | 2016-02-11 |
| WO2014078309A1 (en) | 2014-05-22 |
| JP2015536997A (ja) | 2015-12-24 |
| US20200331861A1 (en) | 2020-10-22 |
| US9765031B2 (en) | 2017-09-19 |
| US20180022705A1 (en) | 2018-01-25 |
| US20230219896A1 (en) | 2023-07-13 |
| CA2889697C (en) | 2023-03-14 |
| CA2889697A1 (en) | 2014-05-22 |
| US11939297B2 (en) | 2024-03-26 |
| US20230202983A1 (en) | 2023-06-29 |
| CN104884057A (zh) | 2015-09-02 |
| US10683270B2 (en) | 2020-06-16 |
| US11485709B2 (en) | 2022-11-01 |
| US10787419B2 (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN03733A (https=) | ||
| NO2023032I1 (en) | Deucravacitinib or a pharmaceutically acceptable salt thereof | |
| NO2025034I1 (no) | Remdesivir or a pharmaceutically acceptable salt or ester thereof - forlengelse | |
| NO2022043I1 (en) | Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride | |
| NO2021034I1 (no) | pemigatinib or a pharmaceutically acceptable salt thereof | |
| NO2021041I1 (no) | remimazolam or a pharmaceutically acceptable salt thereof | |
| EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
| PL2768479T3 (pl) | Zaróbki do kompozycji terapeutycznych zawierających nikotynę | |
| ZA201407726B (en) | Pharmaceutical compositions for combination therapy | |
| DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
| PL2560624T3 (pl) | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku | |
| ZA201501977B (en) | Orally administered medical composition | |
| IL228709A0 (en) | Dosage unit form for oral administration | |
| EP3082817A4 (en) | Compositions for drug administration | |
| IN2014MN02598A (https=) | ||
| GB201216018D0 (en) | Pharmacologically active compounds | |
| IL231485A0 (en) | Medicinal compounds are immune to interference | |
| MY187718A (en) | Pharmaceutical formulations | |
| IL234363B (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| PL2672973T3 (pl) | Schemat podawania nitrokatecholi | |
| IL229591A0 (en) | Addition of medicine | |
| PL2814473T3 (pl) | Kompozycje farmaceutyczne do terapii skojarzonej | |
| EP2864328B8 (en) | Pharmaceutically active compounds | |
| DK2420219T3 (da) | Indgivelsesport | |
| HUP1100641A2 (en) | A new diaza-benzofluoranthene derivate as drug |